In trial NCT03855371, early data suggest that arsenic trioxide could selectively target mutant p53, potentially reversing immune evasion in AML by removing dysfunctional p53 isoforms that suppress immune gene expression 54. The gene discussed is TP53; the disease is acute myeloid leukemia.